We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00484679
Recruitment Status : Completed
First Posted : June 11, 2007
Results First Posted : June 20, 2014
Last Update Posted : June 29, 2018
National Alopecia Areata Foundation
Information provided by (Responsible Party):
University of Minnesota

Brief Summary:
The purpose of the study is to see whether treating alopecia areata with injections of the corticosteroid, Triamcinolone acetonide 10mg/cc (Kenalog-10), has an impact on the adrenal glands.

Condition or disease Intervention/treatment Phase
Alopecia Areata Drug: Triamcinolone Acetonide 10 mg/mL (Kenalog-10) Phase 2

Detailed Description:
  1. To determine the effects of intralesional Triamcinolone Acetonide 10mg/cc (Kenalog 10) use for the treatment of alopecia areata on adrenal function.
  2. To evaluate the efficacy of intralesional corticosteroids (Kenalog-10)on hair regrowth in moderate to severe alopecia areata.

18 subjects with moderate to severe alopecia areata were enrolled and 15 subjects completed all study visits.

Subjects underwent intralesional triamcinolone acetonide (10mg/cc) (Kenalog-10) injections every 6 weeks for a period of 6 months in the General Clinical Research Center (GCRC). This period was followed by a 6 week, injection-free, safety follow-up visit. Adrenal function was assessed by utilization of the Low Dose Adrenocorticotropic Hormone Stimulation Test (ACTH) which measures adrenal gland production of cortisol after exogenously administered ACTH. Serum blood draws of 3 mL were done at baseline and 6-week intervals at the start of each scheduled appointment for intralesional treatment at approximately 0800 hours. Two blood draws were taken at time 0 and again 30 minutes after a 1 mcg bolus dose of synthetic ACTH (Cortrosyn).

Patients underwent their scheduled course of intralesional corticosteroid (Kenalog-10) injections and other study data was collected, such as SALT scores and physician assessments of AA, during the time between blood draws.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata
Study Start Date : May 2007
Actual Primary Completion Date : June 2009
Actual Study Completion Date : March 2011

Arm Intervention/treatment
Experimental: 1
Patients receiving Triamcinolone Acetonide 10 ml (Kenalog-10) intralesional injections.
Drug: Triamcinolone Acetonide 10 mg/mL (Kenalog-10)
Triamcinolone Acetonide 10 mg/ml (Kenalog-10) intralesional injection
Other Name: Kenalog 10

Primary Outcome Measures :
  1. Mean Change in Cortisol Levels From Baseline to Week 24 [ Time Frame: baseline, week 24 ]
    Mean change in cortisol levels from baseline to week 24 after four triamcinolone acetonide 10 ml injections 6 weeks apart.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subject has clinical diagnosis of alopecia areata.
  • Written informed consent and HIPAA authorization have been obtained.

    • Female subjects of childbearing potential have a negative pregnancy test and agree to use an acceptable method of birth control to prevent pregnancy.
  • In the opinion of the investigator, subject is a candidate for intralesional therapy for alopecia areata.
  • Subject agrees to comply with protocol requirements and attend all required study visits and is considered to be a good study subject.
  • Subject meets concomitant medication washout requirements.
  • Subject is >/= 18 years of age.

Exclusion Criteria:

  • Subject has alopecia universalis.
  • Subject has known adrenocortical insufficiency or Cushing's Syndrome.
  • Subject is pregnant or lactating.
  • Subject has current controlled or uncontrolled bacterial, viral, fungal, atypical, or opportunistic infections.
  • Subject possesses hypersensitivity to cortrosyn or Triamcinolone Acetonide (Kenalog-10) or any component of their formulation.
  • Subject is currently or has undergone therapy for malignancy within the past five years.
  • Subject has history of substance abuse within the past five years.
  • Subject has used oral corticosteroids within the past 12 months.
  • Subject has concurrent use of phenytion rifampin, phenobarbital, mitotane, or other formulations of corticosteroid medications.
  • Subject has any medical condition that, in the judgement of the investigator, would jeopardize the subject's safety following exposure to the administered medications.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00484679

Layout table for location information
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
University of Minnesota
National Alopecia Areata Foundation
Layout table for investigator information
Study Director: Maria K Hordinsky, MD University of Minnesota
Layout table for additonal information
Responsible Party: University of Minnesota
ClinicalTrials.gov Identifier: NCT00484679    
Other Study ID Numbers: 0609M91989
First Posted: June 11, 2007    Key Record Dates
Results First Posted: June 20, 2014
Last Update Posted: June 29, 2018
Last Verified: April 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Alopecia Areata
Hair Diseases
Skin Diseases
Pathological Conditions, Anatomical
Triamcinolone Acetonide
Triamcinolone hexacetonide
Triamcinolone diacetate
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Immunosuppressive Agents
Immunologic Factors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action